247 related articles for article (PubMed ID: 32404973)
1. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
Lukas M; Velten B; Sellner L; Tomska K; Hüellein J; Walther T; Wagner L; Muley C; Wu B; Oleś M; Dietrich S; Jethwa A; Bohnenberger H; Lu J; Huber W; Zenz T
Leukemia; 2020 Nov; 34(11):2934-2950. PubMed ID: 32404973
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
3. Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
Pettijohn EM; Ma S
Curr Hematol Malig Rep; 2017 Feb; 12(1):20-28. PubMed ID: 28155013
[TBL] [Abstract][Full Text] [Related]
4. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
5. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
7. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
8. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
[TBL] [Abstract][Full Text] [Related]
9. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
10. Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.
Wolf C; Maus C; Persicke MRO; Filarsky K; Tausch E; Schneider C; Döhner H; Stilgenbauer S; Lichter P; Höfer T; Mertens D
Int J Cancer; 2022 Sep; 151(5):783-796. PubMed ID: 35527719
[TBL] [Abstract][Full Text] [Related]
11. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
13. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
14. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
[TBL] [Abstract][Full Text] [Related]
15. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
16. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
[TBL] [Abstract][Full Text] [Related]
17. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
20. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
Slinger E; Thijssen R; Kater AP; Eldering E
Leukemia; 2017 Dec; 31(12):2601-2607. PubMed ID: 28462919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
